A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy

NCT06476899 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

CLL/SLL

Interventions

DRUG: orelabrutinib
DRUG: FCR/BR
DRUG: BTK inhibitor

Sponsor

Fei Li